Brief: Igc Pharma - Continues To Make Significant Progress Advancing Lead Alzheimer's Candidate Through Phase 2 Clinical Trials

IGC Pharma

14/08/2023 14:17

Aug 14 (Reuters) - IGC Pharma Inc  IGC.A :
    * IGC PHARMA REPORTS FIRST QUARTER RESULTS; COMPANY
CONTINUES TO
MAKE SIGNIFICANT PROGRESS ADVANCING ITS LEAD ALZHEIMER’S
CANDIDATE THROUGH PHASE 2 CLINICAL TRIALS
    * IGC PHARMA INC: QTRLY LOSS PER SHARE $0.04

Source text for Eikon:  ID:nBw5JMD9ba 
Further company coverage:  IGC.A 

 ((Reuters.Briefs@thomsonreuters.com;))